Rabbit Polyclonal FGFR3 Antibody

Fibroblast Growth Factor Receptor 3 (FGFR3) is a transmembrane tyrosine kinase receptor that plays critical roles in regulating cell proliferation, differentiation, and survival. It binds to fibroblast growth factors (FGFs), triggering downstream signaling pathways such as MAPK and PI3K-AKT. Aberrant FGFR3 activity, caused by mutations, amplifications, or overexpression, is implicated in various diseases, including skeletal dysplasia (e.g., achondroplasia), bladder cancer, multiple myeloma, and cervical cancer. FGFR3-targeting antibodies have emerged as promising tools for research, diagnostics, and therapeutics. Therapeutically, monoclonal antibodies (e.g., B-701. MFGR1877S) and antibody-drug conjugates are designed to block ligand binding, inhibit receptor dimerization, or deliver cytotoxic payloads to FGFR3-overexpressing cancer cells. In diagnostics, FGFR3 antibodies aid in detecting overexpression or mutation status in tumor samples, guiding personalized treatment strategies. Research-grade antibodies are widely used to study FGFR3's biological functions and signaling mechanisms. Challenges include minimizing off-target effects due to FGFR family homology and addressing resistance mechanisms. Recent advances in antibody engineering, such as bispecific antibodies or nanobodies, aim to enhance specificity and therapeutic efficacy. FGFR3 antibodies represent a growing field bridging molecular pathology and precision medicine.